Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PAOX | Q6QHF9 | 5/20 | 1.00 |
| ▸ | HIF1A | Q16665 | 2/20 | 0.76 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.76 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.76 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.59 |
| ▸ | SIRT6 | Q8N6T7 | 1/20 | 0.51 |
| ▸ | SIRT1 | Q96EB6 | 1/20 | 0.51 |
| ▸ | GNAI3 | P08754 | 1/20 | 0.49 |
| ▸ | GNAO1 | P09471 | 1/20 | 0.49 |
| ▸ | GNAI1 | P63096 | 1/20 | 0.49 |
| ▸ | MAOA | P21397 | 1/20 | 0.48 |
| ▸ | MAOB | P27338 | 1/20 | 0.48 |
| ▸ | KDM4A | O75164 | 1/20 | 0.46 |
| ▸ | TET2 | Q6N021 | 1/20 | 0.46 |
| ▸ | DOHH | Q9BU89 | 1/20 | 0.46 |
| ▸ | SLC6A5 | Q9Y345 | 2/20 | 0.46 |
| ▸ | TSHR | P16473 | 1/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31532946 | 1.00 | PAOX (1.00) | PAOXHIF1AKDM4EMAPK1ADRA1A | |
| SCHEMBL1409002 | 1.00 | PAOX (1.00) | PAOXHIF1AKDM4EMAPK1ADRA1A | |
| SCHEMBL19816770 | 1.00 | PAOX (1.00) | PAOXHIF1AKDM4EMAPK1ADRA1A | |
| SCHEMBL1408891 | 1.00 | PAOX (1.00) | PAOXHIF1AKDM4EMAPK1ADRA1A | |
| SCHEMBL1409041 | 1.00 | PAOX (1.00) | PAOXHIF1AKDM4EMAPK1ADRA1A | |
| SCHEMBL7552315 | 1.00 | PAOX (1.00) | PAOXHIF1AKDM4EMAPK1ADRA1A | |
| SCHEMBL285321 | 1.00 | PAOX (1.00) | PAOXHIF1AKDM4EMAPK1ADRA1A | |
| SCHEMBL12006469 | 1.00 | PAOX (1.00) | PAOXHIF1AKDM4EMAPK1ADRA1A | |
| SCHEMBL21842271 | 1.00 | PAOX (1.00) | PAOXHIF1AKDM4EMAPK1ADRA1A | |
| SCHEMBL1409025 | 1.00 | PAOX (1.00) | PAOXHIF1AKDM4EMAPK1ADRA1A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 410 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2026099467-A1 | COMPOSITION FOR USE IN PROMOTING BRAIN DEVELOPMENT AND FUNCTIONING | Société des Produits Nestlé S.A. (CH) | 2026-05-15 | — | — | WO | claimed |
| US-12584924-B2 | Compositions and methods for diagnosing and treating chronic kidney disease | SOCIETE DES PRODUITS NESTLE S.A. (CH) | 2026-03-24 | — | — | US | claimed |
| US-20260007716-A1 | DESLORELIN FOR ATTENUATION OF ANIMAL URINE ODOR | VIRBAC (FR) | 2026-01-08 | — | — | US | claimed |
| CN-119654133-A | Desertraline for reducing animal urine odors | 维克公司 | 2025-03-18 | — | — | CN | claimed |
| US-20250027938-A1 | METABOLIC SIGNATURE FOR PREDICTION OF MUCOSAL INFLAMMATION AND MICROBIAL COMPOSITION | IMPERIAL COLLEGE INNOVATIONS LIMITED (GB) | 2025-01-23 | — | — | US | claimed |
| EP-4457513-A1 | COMPOSITIONS AND METHODS FOR DIAGNOSING AND TREATING CHRONIC KIDNEY DISEASE | Société des Produits Nestlé S.A. (CH) | 2024-11-06 | — | — | EP | claimed |
| US-20240290431-A1 | BIOMARKER AND DIAGNOSIS SYSTEM FOR COLORECTAL CANCER DETECTION | HANGZHOU CALIBRA DIAGNOSTICS CO LTD (CN) | 2024-08-29 | — | — | US | claimed |
| CN-118435054-A | Compositions and methods for diagnosing and treating chronic kidney disease | 雀巢产品有限公司 | 2024-08-02 | — | — | CN | claimed |
| US-20240241107-A1 | SERUM METABOLOMICS RELATED TO CHIMERIC ANTIGEN RECEPTOR (CAR) T-CELL THERAPY | BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM (US) | 2024-07-18 | — | — | US | claimed |
| EP-4370919-A1 | METABOLIC SIGNATURE FOR PREDICTION OF MUCOSAL INFLAMMATION AND MICROBIAL COMPOSITION | Imperial College Innovations Limited (GB) | 2024-05-22 | — | — | EP | claimed |
| CN-106906175-A | Method and recombinant microorganism for producing cadaverine | 巴斯夫欧洲公司 | 2017-06-30 | — | — | CN | claimed |
| US-8741623-B2 | Process for the production of cadaverine | BASF SE (DE) | 2014-06-03 | — | — | US | claimed |
| CN-103492553-A | Processes and recombinant microorganisms for the production of cadaverine | BASF SE | 2014-01-01 | — | — | CN | claimed |
| US-20120295317-A1 | Processes and Recombinant Microorganisms for the Production of Cadaverine | BASF SE (DE) | 2012-11-22 | — | — | US | claimed |
| EP-2513302-A1 | PROCESSES AND RECOMBINANT MICROORGANISMS FOR THE PRODUCTION OF CADAVERINE | BASF SE (DE) | 2012-10-24 | — | — | EP | claimed |
| CN-102753682-A | Method and recombinant microorganism for the production of cadaverine | BASF SE | 2012-10-24 | — | — | CN | claimed |
| WO-2011073278-A1 | PROCESSES AND RECOMBINANT MICROORGANISMS FOR THE PRODUCTION OF CADAVERINE | BASF SE (DE) | 2011-06-23 | — | — | WO | claimed |
| EP-0297533-B1 | Novel acetylpolyamine amidohydrolase | KYOWA HAKKO KOGYO KK (JP) | 1994-06-01 | — | — | EP | claimed |
| US-4981788-A | BIOSYNTHESIS | KYOWA HAKKO KOGYO CO., LTD. (JP) | 1991-01-01 | — | — | US | claimed |
| EP-0297533-A2 | Novel acetylpolyamine amidohydrolase | KYOWA HAKKO KOGYO CO., LTD. (JP) | 1989-01-04 | — | — | EP | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12584924-B2 | Compositions and methods for diagnosing and treating chronic kidney disease | GLS, AADAT, FGF23 | PAOX 4517/4885HIF1A 37/4885KDM4E 124/4885 |
| US-20260007716-A1 | DESLORELIN FOR ATTENUATION OF ANIMAL URINE ODOR | FSHR, GNRHR, SHBG | PAOX 4209/4885HIF1A 2018/4885KDM4E 3275/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.